Results 141 to 150 of about 20,052 (248)

Reaching an ACCORD on Glycemia and Systolic Blood Pressure Targets in Type 2 Diabetes Mellitus [PDF]

, 2018
MacDonald, Thomas M., Mackenzie, Isla S.
core   +2 more sources

Emerging Role of Ferroptosis in Diabetes and Associated Complications: When Metabolic Dysregulation Meets Cell Death

Cell Proliferation, EarlyView.
This study identifies ferroptosis as a key driver of diabetes and its complications via iron metabolism and lipid peroxidation, elucidates organelle interactions underlying cell vulnerability, and provides insights for targeted therapies against metabolic disorders.
Zheng Wang, Ying Zhang, Yue Xu, Mengyuan Yang, Yuan Wei, Yuan Li, Tongyue Yang, Xu Wang, Chaona Yang, Qi Feng, Guolan Xing   +10 more
wiley   +1 more source

Diabetes management in people undergoing metabolic‐bariatric surgery: A guideline from the Joint British Diabetes Societies for Inpatient Care (JBDS‐IP) Group

Diabetic Medicine, EarlyView.
Abstract The global prevalence of obesity and diabetes continues to rise, with metabolic‐bariatric surgery recognised as an effective intervention for obesity and type 2 diabetes, offering potential for type 2 diabetes remission and improved glycaemic control. This guideline, developed by the Joint British Diabetes Societies for Inpatient Care (JBDS‐IP)
Jeffrey W. Stephens, Ketan Dhatariya, Andrew J. Beamish, Dimitri J. Pournaras, Alexander D. Miras, Nader Raafat, Georgia Noble‐Bell, Rachel Cadwallader Buckland, Omar G. Mustafa   +8 more
wiley   +1 more source

Efficacy and safety of once‐weekly insulins in type 2 diabetes: A systematic review and meta‐analysis

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Once‐weekly (OW) insulins represent a promising strategy to reduce injection burden and improve adherence in type 2 diabetes management. This meta‐analysis aimed to quantify pooled effect sizes for key biological and clinical outcomes, integrating new findings from the five large trials published in 2025.
Olivier Bourron, Damien Denimal
wiley   +1 more source

Semaglutide as a potential tool in pre-lung transplant weight loss optimization. [PDF]

JCEM Case Rep
Ali R, Keyt H, Solis-Herrera C, Escobar-Vasco M.   +3 more
europepmc   +1 more source

Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX‐SEMA 2.4 mg, an Italian real‐world study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate real‐world clinical use of semaglutide in obese patients, focusing on titration, tolerability and short‐term efficacy. Materials and Methods This retrospective study included obese patients treated with the weekly injectable semaglutide.
Simone Pampanelli, Stefano Terzoni, Paola Pantanetti, Chiara Di Loreto, Alessio Mazzieri, Giovanni Cangelosi, Sara Alberti, Cristina Badiali, Ilenia Grandone, Sara Migliarelli, Maria Grazia Castagna, Mariaclaudia Cerrai Ceroni, Nicoletta Benenati   +12 more
wiley   +1 more source

Not All GLP-1 Receptor Agonists Are Alike: Real-World Evidence of Differential Endocrine and Dermatologic Safety. [PDF]

Diabetes Metab Res Rev
Lee N, Kim Y.
europepmc   +1 more source

Ozempic (semaglutide) versus Nonpharmacologic Interventions For Weight Management in Overweight Individuals [PDF]

Ozempic (semaglutide) is a medication prescribed for individuals managing Type 2 Diabetes Mellitus by mimicking the action of a hormone called GLP-1, helping to regulate glucose levels by stimulating insulin secretion and reducing glucagon secretion ...
DiGirolamo, Emma, Gillmore, Callie, Jacey, Elena N, Jennings, Lily, Kane, Emily   +4 more
core   +1 more source

Providing holistic care for patients with metabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD), characterised by hepatic steatosis and metabolic dysfunction (i.e., obesity, type 2 diabetes, dyslipidaemia, and hypertension), is affecting over 30% of the adult population worldwide.
Lanlan Chen, Paul Horn, Frank Tacke
wiley   +1 more source

The Ethics of Ozempic and Wegovy. [PDF]

J Med Ethics
Ryan N, Savulescu J.
europepmc   +1 more source